English
HLA-C*08:02 Lentivirus
HLA-C*08:02 Lentivirus
Artikelnummer
BPS78930
Verpackungseinheit
500 µl x 2
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: • Expression of human HLA-C*08:02 in cells of interest.• Generate cell pools or stable cell lines expressing HLA-C*08:02 following puromycin selection.
Background: Human Leukocyte Antigen-C (HLA-C) are MHC (major histocompatibility complex) I heavy chain receptor, composed of HLA-C and β2-microglobulin (B2M). HLA-C is present in all cells and exists as several haplotypes due to the diversity of HLA-C genes. C*08:02 represents one such haplotype. HLA class I present neoantigen derived peptides to the cell surface, allowing them to be recognized by T cells, via TCR (T cell receptors). Cancer immunotherapy has been taking advantage of that mechanism, by engineering T cells to express TCRs able to recognize specific cancer immunogens. In 2016 the use of HLA-C*08:02-restricted TIL (tumor infiltrating lymphocytes) targeting specifically KRAS (Kirsten rat sarcoma virus) G12D mutation in lung cancer resulted in positive results. Last year a similar approach was pursued in a patient with metastatic pancreatic cancer and resulted in regression of the disease. The study of HLA-C*08:02-restricted TIL expressing TCR against other neoantigens may prove beneficial in cancer therapy.
Description: HLA-C*08:02 Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses result in expression of human HLA-C*08:02 driven by an EF1a promoter and a puromycin selection marker
Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
References: Leidner R., et al., 2022 N Engl J Med 386:2112-2119
Tran E., et al., 2016 N Eng J Med 375:2255-2262.
Applications: • Expression of human HLA-C*08:02 in cells of interest.• Generate cell pools or stable cell lines expressing HLA-C*08:02 following puromycin selection.
Background: Human Leukocyte Antigen-C (HLA-C) are MHC (major histocompatibility complex) I heavy chain receptor, composed of HLA-C and β2-microglobulin (B2M). HLA-C is present in all cells and exists as several haplotypes due to the diversity of HLA-C genes. C*08:02 represents one such haplotype. HLA class I present neoantigen derived peptides to the cell surface, allowing them to be recognized by T cells, via TCR (T cell receptors). Cancer immunotherapy has been taking advantage of that mechanism, by engineering T cells to express TCRs able to recognize specific cancer immunogens. In 2016 the use of HLA-C*08:02-restricted TIL (tumor infiltrating lymphocytes) targeting specifically KRAS (Kirsten rat sarcoma virus) G12D mutation in lung cancer resulted in positive results. Last year a similar approach was pursued in a patient with metastatic pancreatic cancer and resulted in regression of the disease. The study of HLA-C*08:02-restricted TIL expressing TCR against other neoantigens may prove beneficial in cancer therapy.
Description: HLA-C*08:02 Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses result in expression of human HLA-C*08:02 driven by an EF1a promoter and a puromycin selection marker
Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
References: Leidner R., et al., 2022 N Engl J Med 386:2112-2119
Tran E., et al., 2016 N Eng J Med 375:2255-2262.
| Artikelnummer | BPS78930 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 78930 |
| Green Labware | Nein |
| Verpackungseinheit | 500 µl x 2 |
| Mengeneinheit | PAK |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
